The Manitoba human papillomavirus vaccine surveillance and evaluation system.
BACKGROUND
With the recent introduction of a human papillomavirus (HPV) vaccine in Canada, it is important to establish surveillance and evaluation programs that not only track the uptake of the vaccine, but also assess its safety and its impact on: distribution of HPV type, cervical cancer screening programs, the incidence of anogenital warts, precancerous lesions and various cancers, and sexual behaviour.


METHODS
Administrative databases, registries and questionnaire information are being linked to identify people receiving the HPV vaccine and to develop an evaluation system.


CONCLUSIONS
The availability of extensive linkable databases in Manitoba allows for the development of a comprehensive HPV vaccine surveillance and evaluation system that can address many of the questions related to the HPV vaccine. Aspects of the Manitoba surveillance and evaluation system could be implemented in other provinces that have similar databases.
Kliewer
Erich V
EV
CancerCare Manitoba, Winnipeg, Manitoba. Erich.Kliewer@cancercare.mb.ca
Demers
Alain A
AA
Brisson
Marc
M
Severini
Alberto
A
Lotocki
Robert
R
Elias
Brenda
B
Hammond
Gregory
G
Wurtak
George
G
D000293:Adolescent; D000328:Adult; D052685:Alphapapillomavirus / Q000187:drug effects*; D002648:Child; D005260:Female; D006801:Humans; D008350:Manitoba; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D011159:Population Surveillance; D012042:Registries; D055815:Young Adult
D053918:Papillomavirus Vaccines